RealFeedApp Intismeran reduces recurrence risk by 42%
The Intismeran mRNA vaccine combined with Keytruda reduced the risk of recurrence or death by 42% compared to Keytruda alone. Researchers now aim to apply this personalized approach to other tumor types.
- Field
- gene therapy
- What they did
- Researchers demonstrated that the personalized mRNA vaccine Intismeran, combined with the drug Keytruda, reduced the risk of recurrence or death by 42% compared to Keytruda alone.
- Why it matters
- This result is crucial for oncology as it proves the effectiveness of this new treatment method and paves the way for broader application of cancer vaccines against melanoma and other tumor types.
#mrna vaccine#immunotherapy#melanoma#clinical trial#merck#moderna
